Journal of Clinical Oncology, Vol 12, 1390-1393, Copyright © 1994 by American Society of Clinical Oncology

ARTICLES

Salvage chemotherapy in patients with extragonadal nonseminomatous germ cell tumors: the Indiana University experience

SB Saxman, CR Nichols and LH Einhorn
Indiana University School of Medicine, Division of Hematology/Oncology, Indianapolis 46202.

PURPOSE: Patients with relapsed extragonadal germ cell tumors (EGCT) are usually treated in an identical fashion as patients with recurrent testicular cancer. However, little is known about the long-term outcome in these patients and whether they have comparable results to patients with a testicular primary tumor. The purpose of this study was to evaluate the effect of salvage chemotherapy on long-term survival in patients with EGCT. MATERIALS AND METHODS: We conducted a retrospective review of 73 patients with relapsed extragonadal nonseminomatous germ cell tumors (GCTs) treated at Indiana University between 1976 and 1993. All patients received cisplatin-containing regimens as primary chemotherapy. RESULTS: Only five of 73 patients (7%) were long-term disease-free survivors after salvage chemotherapy. The remaining 68 patients are either dead of disease or toxicity (n = 63), or alive with progressive disease (PD) (n = 5). Twenty-eight patients received high- dose chemotherapy with autologous bone marrow transplant (ABMT) at some point during their disease, and none of these patients are continuously disease-free. CONCLUSION: Although similar salvage chemotherapy strategies will cure approximately 30% of patients with recurrent testicular cancer, new approaches are needed for EGCT.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				S. M. Radaideh, V. C. Cook, K. A. Kesler, and L. H. Einhorn Outcome following resection for patients with primary mediastinal nonseminomatous germ-cell tumors and rising serum tumor markers post-chemotherapy Ann. Onc., November 4, 2009; (2009) mdp516v1. [Abstract] [Full Text] [PDF]

				C. H. Kang, Y. T. Kim, S.-H. Jheon, S.-w. Sung, and J. H. Kim Surgical Treatment of Malignant Mediastinal Nonseminomatous Germ Cell Tumor Ann. Thorac. Surg., February 1, 2008; 85(2): 379 - 384. [Abstract] [Full Text] [PDF]

				G. V. Kondagunta, J. Bacik, J. Sheinfeld, D. Bajorin, M. Bains, L. Reich, J. Deluca, A. Budnick, N. Ishill, M. Mazumdar, et al. Paclitaxel Plus Ifosfamide Followed by High-Dose Carboplatin Plus Etoposide in Previously Treated Germ Cell Tumors J. Clin. Oncol., January 1, 2007; 25(1): 85 - 90. [Abstract] [Full Text] [PDF]

				G. V. Kondagunta and R. J. Motzer Chemotherapy for Advanced Germ Cell Tumors J. Clin. Oncol., December 10, 2006; 24(35): 5493 - 5502. [Abstract] [Full Text] [PDF]

				P. M. Bedano, M. J. Brames, S. D. Williams, B. E. Juliar, and L. H. Einhorn Phase II Study of Cisplatin Plus Epirubicin Salvage Chemotherapy in Refractory Germ Cell Tumors J. Clin. Oncol., December 1, 2006; 24(34): 5403 - 5407. [Abstract] [Full Text] [PDF]

				B. Oyan and Y. Koc Is it time to discontinue using high-dose chemotherapy for salvage of patients with advanced germ-cell tumors failing first-line platinum chemotherapy? Ann. Onc., February 1, 2006; 17(2): 349 - 350. [Full Text] [PDF]

				U. De Giorgi, T. Demirer, H. Wandt, C. Taverna, W. Siegert, M. Bornhauser, T. Kozak, G. Papiani, M. Ballardini, G. Rosti, et al. Second-line high-dose chemotherapy in patients with mediastinal and retroperitoneal primary non-seminomatous germ cell tumors: the EBMT experience Ann. Onc., January 1, 2005; 16(1): 146 - 151. [Abstract] [Full Text] [PDF]

				H. Sakurai, H. Asamura, K. Suzuki, S.-i. Watanabe, and R. Tsuchiya Management of Primary Malignant Germ Cell Tumor of the Mediastinum Jpn. J. Clin. Oncol., July 1, 2004; 34(7): 386 - 392. [Abstract] [Full Text] [PDF]

				B. P. Schneider, K. A. Kesler, J. A. Brooks, C. Yiannoutsos, and L. H. Einhorn Outcome of Patients With Residual Germ Cell or Non-Germ Cell Malignancy After Resection of Primary Mediastinal Nonseminomatous Germ Cell Cancer J. Clin. Oncol., April 1, 2004; 22(7): 1195 - 1200. [Abstract] [Full Text] [PDF]

				D. A. Vaena, R. Abonour, and L. H. Einhorn Long-Term Survival After High-Dose Salvage Chemotherapy for Germ Cell Malignancies With Adverse Prognostic Variables J. Clin. Oncol., November 15, 2003; 21(22): 4100 - 4104. [Abstract] [Full Text] [PDF]

				J. T. Hartmann, C. R. Nichols, J.-P. Droz, A. Horwich, A. Gerl, S. D. Fossa, J. Beyer, J. Pont, L. Kanz, L. Einhorn, et al. Prognostic variables for response and outcome in patients with extragonadal germ-cell tumors Ann. Onc., July 1, 2002; 13(7): 1017 - 1028. [Abstract] [Full Text] [PDF]

				C. Bokemeyer, C. R. Nichols, J.-P. Droz, H.-J. Schmoll, A. Horwich, A. Gerl, S. D. Fossa, J. Beyer, J. Pont, L. Kanz, et al. Extragonadal Germ Cell Tumors of the Mediastinum and Retroperitoneum: Results From an International Analysis J. Clin. Oncol., April 1, 2002; 20(7): 1864 - 1873. [Abstract] [Full Text] [PDF]

				J. Beyer, S. Stenning, A. Gerl, S. Fossa, and W. Siegert High-dose versus conventional-dose chemotherapy as first-salvage treatment in patients with non-seminomatous germ-cell tumors: a matched-pair analysis Ann. Onc., April 1, 2002; 13(4): 599 - 605. [Abstract] [Full Text] [PDF]

				J. T. Hartmann, L. Einhorn, C. R. Nichols, J.-P. Droz, A. Horwich, A. Gerl, S. D. Fossa, J. Beyer, J. Pont, H.-J. Schmoll, et al. Second-Line Chemotherapy in Patients With Relapsed Extragonadal Nonseminomatous Germ Cell Tumors: Results of an International Multicenter Analysis J. Clin. Oncol., March 15, 2001; 19(6): 1641 - 1648. [Abstract] [Full Text] [PDF]

				J. Vuky, M. Bains, J. Bacik, G. Higgins, D. F. Bajorin, M. Mazumdar, G. J. Bosl, and R. J. Motzer Role of Postchemotherapy Adjunctive Surgery in the Management of Patients With Nonseminoma Arising From the Mediastinum J. Clin. Oncol., February 1, 2001; 19(3): 682 - 688. [Abstract] [Full Text] [PDF]

				S. Bhatia, R. Abonour, P. Porcu, R. Seshadri, C.R. Nichols, K. Cornetta, and L.H. Einhorn High-Dose Chemotherapy as Initial Salvage Chemotherapy in Patients With Relapsed Testicular Cancer J. Clin. Oncol., October 19, 2000; 18(19): 3346 - 3351. [Abstract] [Full Text] [PDF]

				K. A. Kesler, K. M. Rieger, K. N. Ganjoo, M. Sharma, N. S. Fineberg, L. H. Einhorn, and J. W. Brown PRIMARY MEDIASTINAL NONSEMINOMATOUS GERM CELL TUMORS: THE INFLUENCE OF POSTCHEMOTHERAPY PATHOLOGY ON LONG-TERM SURVIVAL AFTER SURGERY J. Thorac. Cardiovasc. Surg., October 1, 1999; 118(4): 692 - 701. [Abstract] [Full Text] [PDF]